Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: DanZ who wrote (819)	8/29/1999 6:55:00 PM
From: Mad2	Read Replies (2) \| Respond to of 5582

Dan, I dont think GUMM will have any problem meeting demand as I don't believe they will experience the top line growth you and Howard speculate on. If they did see that type of growth your and Howards oversimplification of how they would finance would result in additional dilutive financing, yet as GUMM won't get there there is little need to dwell on that. By the way, Wrigley has 255 times the sales of GUMM, 100 times the cash (giving GUMM 4.0 mil from the Citidal deal), no debt of which GUMM's debt to equity is 1.0 and earns 300 mil/year at a rate of 15% after tax. Year WWY's market capitalization is on 88 times that of GUMM. GUMM is grossly overvalued. Mad2